Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537103 | 1.00 | CHRM3 (0.61) | CHRM3ADRB2 | |
| SCHEMBL3536476 | 0.93 | CHRM3 (0.61) | CHRM3ADRB2 | |
| SCHEMBL3539460 | 0.93 | CHRM3 (0.61) | CHRM3ADRB2 | |
| SCHEMBL3538438 | 0.93 | CHRM3 (0.61) | CHRM3ADRB2 | |
| SCHEMBL3146753 | 0.92 | CHRM3 (0.58) | CHRM3ADRB2 | |
| SCHEMBL3138369 | 0.92 | CHRM3 (0.58) | CHRM3ADRB2 | |
| SCHEMBL3538699 | 0.92 | CHRM3 (0.63) | CHRM3ADRB2 | |
| SCHEMBL3532701 | 0.91 | CHRM3 (0.59) | CHRM3ADRB2 | |
| SCHEMBL3142617 | 0.90 | CHRM3 (0.57) | CHRM3ADRB2 | |
| SCHEMBL3134770 | 0.90 | CHRM3 (0.56) | CHRM3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569588-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2009-08-04 | — | — | US | claimed |
| EP-1723111-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| WO-2006099166-A1 | CRYSTALLINE FORMS OF A BIPHENYL COMPOUND | THERAVANCE, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| US-20060205949-A1 | Crystalline forms of a biphenyl compound | THERAVANCE, INC. | 2006-09-14 | — | — | US | claimed |
| WO-2005087732-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| US-20050203083-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | claimed |
| US-7858792-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858792-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858792-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7569588-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569588-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569588-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20060205949-A1 | Crystalline forms of a biphenyl compound | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060205949-A1 | Crystalline forms of a biphenyl compound | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
| US-7064215-B2 | Indazole benzimidazole compounds | CHIRON CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
| WO-2005087732-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050203083-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
| US-20030207883-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205949-A1 | Crystalline forms of a biphenyl compound | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2B6, SULT2A1 | CHRM3 1354/4885ADRB2 2372/4885 |
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | CHRM3 3348/4885ADRB2 1823/4885 |
| US-20050203083-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885ADRB2 18/4885 |
| US-20030207883-A1 | Indazole benzimidazole compounds | SLCO1B3, SLCO1B1, SLCO4C1 | CHRM3 2085/4885ADRB2 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.